Skip to Content
Merck

LC/MS (TOF) Analysis of Antiarrhythmic Drugs and Metabolites on Ascentis® Express HILIC

LC/MS (TOF) Analysis of Antiarrhythmic Drugs and Metabolites on Ascentis® Express HILIC application for HPLC

Materials

analytical column

Product No.
Description
Pricing

Ascentis® Express HILIC, 2.7 μm HPLC Column

2.7 μm particle size, L × I.D. 10 cm × 2.1 mm

standard

Product No.
Description
Pricing

(±)-Flecainide solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Lidocaine solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

CONDITIONS

column

Ascentis Express HILIC, 10 cm x 2.1 mm I.D., 2.7 μm particles (53939-U)

mobile phase

[A] 5 mM ammonium formate; [B] 5 mM ammonium formate in acetonitrile; (5:95, A:B, pH 7.0 with formic acid)

flow rate

0.4 mL/min

column temp.

35 °C

detector

ESI(+), full scan, m/z 200-800

injection

0.5 μL

sample

each compound, 300 ng/mL in 1% formic acid acetonitrile:water, 75:25

Description

Analysis Note

The basic nature of these compounds makes them targets for HILIC chromatographic separation. HILIC mobile phases consist of a high composition of acetonitrile, which facilitates the direct analysis of precipitated plasma samples without the need for additional sample solvent exchange. In most cases, the high organic mobile phase also facilitates increased analyte response with ESI(+) MS detection. Separation was performed on an Ascentis Express HILIC Fused-Core HPLC column. High purity solvents provided clean, robust operation. Cerilliant CRMs provided reliable quantification.

Legal Information

Ascentis is a registered trademark of Merck KGaA, Darmstadt, Germany